Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥65 Years with Nonvalvular Atrial Fibrillation

American Journal of Cardiology

Volumn 117, Issue 1, 2016, Pages 54-60

  Salata, Brian M ^a   Hutton, David W ^b,c   Levine, Deborah A ^c,d,e   Froehlich, James B ^c,f   Barnes, Geoffrey D ^c,f  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MEDICARE; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; UNSPECIFIED SIDE EFFECT; COMPLICATION; COST BENEFIT ANALYSIS; DOSE RESPONSE; ECONOMICS; FEMALE; MALE; RETROSPECTIVE STUDY; UNITED STATES;

AGED; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; COST-BENEFIT ANALYSIS; DABIGATRAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; FEMALE; HEALTH EXPENDITURES; HUMANS; MALE; RETROSPECTIVE STUDIES; UNITED STATES; WARFARIN;

EID: 84959250465     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2015.09.048     Document Type: Article

References (21)

1. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P.A. Reilly, E. Themeles, J. Varrone, S. Wang, M. Alings, D. Xavier, J. Zhu, R. Diaz, B.S. Lewis, H. Darius, H. Diener, C.D. Joyner, and L. Wallentin Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
2. Thomson Reuters Red Book 2009 Thomson Reuters Montvale 1032
3. J.V. Freeman, R.P. Zhu, D.K. Owens, A.M. Garber, D.W. Hutton, A.S. Go, P.J. Wang, and M.P. Turakhia Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Ann Intern Med 154 2011 1 11
4. H. Kamel, S.C. Johnston, J.D. Easton, and A.S. Kim Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack Stroke 43 2012 881 883
5. S.V. Shah, and B.F. Gage Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation Circulation 123 2011 2562 2570
6. D.E. Jonas, B. Bryant Shilliday, W.R. Laundon, and M. Pignone Patient time requirements for anticoagulation therapy with warfarin Med Decis Making 30 2010 206 216
7. M.J. Ariesen, S.P. Claus, G.J. Rinkel, and A. Algra Risk factors for intracerebral hemorrhage in the general population: a systematic review Stroke 34 2003 2060 2065
8. Agency for Healthcare Research and Quality 2003 Nationwide Inpatient Sample 2003 Healthcare Cost and Utilization Project Rockville
9. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials Arch Intern Med 154 1994 1449 1457
10. D. Capodanno, P. Capranzano, G. Giacchi, V. Calvi, and C. Tamburino Increasing CHADS2 scores may attenuate the benefit of novel oral anticoagulants versus warfarin in reducing intracranial bleeding Int J Cardiol 161 2012 176 177
11. J. Oldgren, M. Alings, H. Darius, H.C. Diener, M.D. Eikelboom, G. Kamensky, P.A. Reilly, S. Yang, S. Yusuf, L. Wallentin, and S.J. Connolly Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial Ann Intern Med 155 2011 660 667
12. I. Van Wijk, L.J. Kappelle, J. van Gijn, P.J. Koudstaal, C.L. Franke, M. Vermeulen, J.W. Gorter, and A. Algra Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study Lancet 365 2005 2098 2104
13. Z. Zhang, J. Fang, C. Gillespie, G. Wang, Y. Hong, and P.W. Yoon Age-specific gender differences in in-hospital mortality by type of acute myocardial infarction Am J Cardiol 109 2012 1097 1103
14. E. Arias United States life tables, 2004 Natl Vital Stat Rep 56 2007 1 40
15. J.E. Lafata, S.A. Martin, S. Kaatz, and R.E. Ward The cost-effectiveness of different management strategies for patients on chronic warfarin therapy J Gen Intern Med 15 2000 31 37
16. T. Davidson, M. Husberg, M. Janzon, J. Oldgren, and L.Å. Levin Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden Eur Heart J 24 2012 177 183
17. P.J. Neumann, J.T. Cohen, and M.C. Weinstein Updating cost-effectiveness - the curious resilience of the $50,000-per-QALY threshold N Engl J Med 371 2014 796 797
18. S.V. Sorensen, A.R. Kansal, S. Connolly, S. Peng, J. Linnehan, C. Bradley-Kennedy, and J.M. Plumb Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective Thrombos Haemost 105 2011 908 919
19. J. Pink, S. Lane, M. Pirmohamed, and D.A. Hughes Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses BMJ 343 2011 d6333
20. I. Hernandez, S.H. Baik, A. Piñera, and Y. Zhang Risk of bleeding with dabigatran in atrial fibrillation JAMA Intern Med 175 2014 18 24
21. D.B. Mark, J.D. Knight, P.A. Cowper, L. Davidson-Ray, and K.J. Anstrom Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) trial Am Heart J 156 2008 698 705